Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07216027 · ClinicalTrials.gov registry record · Phase 2

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A Phase 2 study of Atopic Dermatitis and Eczema, Atopic, sponsored by Pfizer.

Active
Registry status
Phase 2
Development phase
200
Enrollment target
10
Study locations

NCT07216027 is a Phase 2 study of Atopic Dermatitis and Eczema, Atopic that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07216027, a Phase 2 study of Atopic Dermatitis and Eczema, Atopic, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 years of age or more; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. Eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12, and have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. Participants will have blood and urine tests and must answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to participants receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Conditions Studied

Atopic Dermatitis Eczema, Atopic

Interventions

  • DRUG Placebo
  • DRUG PF-08049820

Study Locations (10)

Florida

  • Gsi Clinical Research - Margate
  • Skin Research of South Florida - Miami

Kanagawa

  • Kosugi Dermatology Clinic - Kawasaki-shi
  • Queen's Square Medical Facilities - Yokohama

Tokyo

  • Nihonbashi Sakura Clinic - Chuo-ku
  • Fukuwa Clinic - Chuo-ku

California

  • Clinical Science Institute - Santa Monica

Tennessee

  • Goodlettsville Dermatology Research - Goodlettsville

Gunma

  • Hattori Dermatology Clinic - Takasaki

Osaka

  • Dermatology and Ophthalmology Kume Clinic - Sakai

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-11-20
Est. Completion 2027-08-23
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07216027

The ClinicalTrials.gov registry entry for NCT07216027 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07216027 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Florida, Kanagawa, Tokyo.

Frequently Asked Questions

What is clinical trial NCT07216027 about?

NCT07216027 is a clinical study titled "A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema". The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. ...

What is the current status of trial NCT07216027?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-20. Estimated completion is 2027-08-23.

What conditions does trial NCT07216027 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Atopic.

What interventions are being tested in trial NCT07216027?

The interventions under investigation include: Placebo (DRUG), PF-08049820 (DRUG).

Who is sponsoring clinical trial NCT07216027?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07216027 being conducted?

This trial has 10 study locations across California, Florida, Tennessee, Gunma, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Eczema, Atopic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.